HUE031939T2 - Orális adagolásra alkalmas, triazol[4,5-d]pirimidin származékot tartalmazó készítmények - Google Patents

Orális adagolásra alkalmas, triazol[4,5-d]pirimidin származékot tartalmazó készítmények Download PDF

Info

Publication number
HUE031939T2
HUE031939T2 HUE07794121A HUE07794121A HUE031939T2 HU E031939 T2 HUE031939 T2 HU E031939T2 HU E07794121 A HUE07794121 A HU E07794121A HU E07794121 A HUE07794121 A HU E07794121A HU E031939 T2 HUE031939 T2 HU E031939T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
mas
aal
weight
agent
Prior art date
Application number
HUE07794121A
Other languages
English (en)
Inventor
Simon Banks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39107049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE031939(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUE031939T2 publication Critical patent/HUE031939T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (4)

  1. ORÁLIS Ä»A£ÖLÄ<m ALKALMAS, T8Í \ZOL|4,S.ÜH*iRiMmtNT SZARMATA-KOI FAR Γ kt * t » H î'*î/ M MÎ ΓK Í*siM#p? i^vnj iKmíok L Gyógyászati készttmény, smegy a ItOvoífccwU'í tariakBasssstK: 5 '\(K- s\í tpvlk\ Κ*'*Ν »»"'i '>' iit N * s ' > ukkc smlb« mo s a V'! '' Ί< L ' k <* ο H -d|pírb«idb-KH)'-5'{2A!sLo>;iöíos!>-cík5o|;sx'íán'LA^sol;; t&amp;M&amp;ovageb amely mawil As k&amp;há?ts» kákm«»^í>sx5st*:Ua5Í^i k&amp;Öanyagok amely hkLosí-patpií-cdiHió?.; sgÉexesl eíosegiLl anyait amely 5sátAkm^kmériyi^|lskö;iS:yfe: egy vagy több keodai*yag«M. % &amp;£ t^ sglsypmkbsk maghaiiioesK gybgyferö kékaimény., sfeb 8:te^p|. ÄpMüii#«# ?s naRtum-utea* ko/ül vaktóatou. A Ai I. Vav.v 2. Igénypontban nvghsmfoacm gyoey&amp;sem; kcsakmêov, ahol a 1l‘H;«,é«, Jpí;S*;/b ) Sp1)-.; kí - Hí'* V+"4sbyorFemlKAloprs>pt?i"ant{!o}"5ApropHt«>j-OH' L^^-ânài'i'UH'LÎ-üjpÎnïîïi-iiî'i' <-íb-I UHK'os v ' u^i-i^UÍ A 's '!' '' 'CHS H''Ht ' ' ! ’ív«
  2. 4, As 1-3 igénypontok bármelyike szerű« megns-ározoö gyógyászait kuKzltmeïsy, ehoí a tAHbtmyag ·;ί-' -74 kVïÎiCg® « mennyiségben cais jeles.
  3. 5, Aï 1-4. Igénypernek bannelyik« sagiöi srsegbaKiro^üt· gyógyászai iömeg’A menny Aígker \,m jden.
  4. 6, Aï 1-1 igéssypuîbok ^ms?pte,'f^8k:5iö^bÄmÄMmimány, Mimi a s^RsFSl etoM&amp;itft anyag 2-ê ?ót«eg6á raensvvfsègie« mejßzu. ?. Aï 1-6. lg««ypontek bánvsely&amp;e seerim me;gha<:aröKeík gycígyáseet! kèmbmbny, almi a ke nyan va g 0Λ- - ; t<8neg*--> fnenayAsgbea vise je les. &amp; *\s \ 'gcrgfoesban snegînt«-v-m g\eg>^atj ke^crsneev, amely a kb veibe ,£ok;a teraaljmswk: ,0-45 UlmesH mem*\?φ&amp;* flS-H«. >m31XLS*2R .'{op*UioV-.>n- ',3 '>':-s\an|4 '-4jeemmbm Väb-m-gbsmbον tetőstt- ctKk>|xto^‘ ' 1"1:'!U-yy~4S tömegé menny «éghm masnitok ;0-3b iibseg'b mennyiségben belbiulsn kaKsomAbs:ao«vütl«i.inAoL 4-fi tí>m«g% m8noYKéglH'»litdí<txí|>f|S»Hceíhitó^,. '·$ tömatTA msftBvneghvm oúrnos«*pfetéayitö^tk<>l^töt5;.éS' A-áas iömeg'-A mentn ingben egy vagy tót<i> keaóasv&amp;giöt··· o g I w\ L íecnVixv'bm a c^ '< >o - ttu-A.s^ ' , ü\ '* 5 M a \o«oan^a^ ffi^pdbNt-' -sAïainb.
HUE07794121A 2006-08-21 2007-08-20 Orális adagolásra alkalmas, triazol[4,5-d]pirimidin származékot tartalmazó készítmények HUE031939T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82308306P 2006-08-21 2006-08-21

Publications (1)

Publication Number Publication Date
HUE031939T2 true HUE031939T2 (hu) 2017-08-28

Family

ID=39107049

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE07794121A HUE031939T2 (hu) 2006-08-21 2007-08-20 Orális adagolásra alkalmas, triazol[4,5-d]pirimidin származékot tartalmazó készítmények

Country Status (35)

Country Link
US (2) US8425934B2 (hu)
EP (1) EP2056832B1 (hu)
JP (2) JP5385139B2 (hu)
KR (1) KR101539467B1 (hu)
CN (1) CN101505754A (hu)
AR (1) AR062451A1 (hu)
AU (2) AU2007288541B9 (hu)
BR (1) BRPI0715712B8 (hu)
CA (1) CA2659328C (hu)
CL (1) CL2007002421A1 (hu)
CO (1) CO6150163A2 (hu)
CY (1) CY1119380T1 (hu)
DK (1) DK2056832T3 (hu)
ES (1) ES2625930T3 (hu)
HR (1) HRP20170694T1 (hu)
HU (1) HUE031939T2 (hu)
IL (2) IL196700A (hu)
LT (1) LT2056832T (hu)
MX (1) MX340403B (hu)
MY (2) MY175009A (hu)
NO (1) NO341787B1 (hu)
NZ (2) NZ574514A (hu)
PH (1) PH12013501627A1 (hu)
PL (1) PL2056832T3 (hu)
PT (1) PT2056832T (hu)
RS (1) RS55884B1 (hu)
RU (2) RU2476223C2 (hu)
SA (1) SA07280442B1 (hu)
SG (1) SG177162A1 (hu)
SI (1) SI2056832T1 (hu)
TW (1) TWI482772B (hu)
UA (1) UA99105C2 (hu)
UY (1) UY30551A1 (hu)
WO (1) WO2008024045A1 (hu)
ZA (1) ZA200900991B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
RU2412176C2 (ru) 2005-08-15 2011-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения бетамиметиков
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
ES2548845T3 (es) 2009-12-23 2015-10-21 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
US20160120869A1 (en) 2013-05-29 2016-05-05 Ratiopharm Gmbh Solid pharmaceutical dosage form
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104644604A (zh) * 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 替格瑞洛倍半水合物胶囊及其制备方法
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
CN104098520B (zh) * 2014-07-23 2016-01-20 张远强 苯基三唑希夫碱类化合物、其制备方法和用途
KR20160012706A (ko) 2014-07-25 2016-02-03 동아에스티 주식회사 서방성 제제
CN105832683A (zh) * 2015-01-15 2016-08-10 成都国弘医药有限公司 一种含有替格瑞洛的片剂
JP2018502894A (ja) * 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3009176A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CN105709230B (zh) * 2016-03-01 2019-05-31 北京鑫兰医药科技有限公司 一种替格瑞洛药物组合物及其制备方法
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
CN107530288B (zh) 2016-04-21 2022-01-25 阿斯利康(瑞典)有限公司 口腔崩解片
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
TR201617983A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022035920A (ja) 2020-08-19 2022-03-04 アストラゼネカ・アクチエボラーグ 併用療法
BR102021011533A2 (pt) * 2021-06-14 2022-12-27 Libbs Farmacêutica Ltda Composição farmacêutica e uso da composição farmacêutica
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
CN101426504A (zh) 2002-02-15 2009-05-06 特瓦药厂私人有限公司 包含规定粒径分布的扎来普隆的粉末组合物和由其制得的药物制品
US20040001885A1 (en) 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
US20060039968A1 (en) 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
US20060189565A1 (en) * 2002-10-22 2006-08-24 Mathur Rajeev S Pharmaceutical compositions of ganciclovir
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
JP2005538038A (ja) * 2003-02-19 2005-12-15 テバ ジョジセルジャール レースベニュタールシャシャーグ 規定された粒子サイズの分布を持つザレプロンを含む粉末組成物、及びそれから作られた医薬製品
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
CN101068570A (zh) 2004-05-13 2007-11-07 贝林格尔·英格海姆国际有限公司 双嘧达莫治疗血小板抑制剂的抗药性的用途
WO2006072878A1 (en) 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
JP5166040B2 (ja) * 2005-01-31 2013-03-21 オプティマー ファーマシューティカルズ、インコーポレイテッド １８員大環状化合物及びその類似化合物
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物

Also Published As

Publication number Publication date
CN101505754A (zh) 2009-08-12
KR20090055561A (ko) 2009-06-02
NZ596700A (en) 2013-05-31
WO2008024045A1 (en) 2008-02-28
MX2009001853A (es) 2009-03-02
KR101539467B1 (ko) 2015-07-24
IL229130A0 (en) 2013-12-31
MY147966A (en) 2013-02-28
SG177162A1 (en) 2012-01-30
DK2056832T3 (en) 2017-05-22
AU2007288541B9 (en) 2011-10-06
SA07280442B1 (ar) 2012-04-07
EP2056832B1 (en) 2017-03-22
MY175009A (en) 2020-06-02
US8425934B2 (en) 2013-04-23
PT2056832T (pt) 2017-05-22
CA2659328A1 (en) 2008-02-28
IL196700A (en) 2014-08-31
ES2625930T3 (es) 2017-07-21
NZ574514A (en) 2012-01-12
EP2056832A4 (en) 2012-12-26
JP2010501554A (ja) 2010-01-21
NO341787B1 (no) 2018-01-22
BRPI0715712A2 (pt) 2014-06-24
TWI482772B (zh) 2015-05-01
EP2056832A1 (en) 2009-05-13
AU2011205164B2 (en) 2014-02-06
HRP20170694T1 (hr) 2017-07-28
LT2056832T (lt) 2017-05-25
CY1119380T1 (el) 2018-02-14
AU2007288541B2 (en) 2011-08-25
IL196700A0 (en) 2009-11-18
US20080058353A1 (en) 2008-03-06
NO20090425L (no) 2009-03-05
RU2012153069A (ru) 2014-06-10
CA2659328C (en) 2015-08-11
MX340403B (es) 2016-07-07
AU2007288541A1 (en) 2008-02-28
US20130131087A1 (en) 2013-05-23
BRPI0715712B8 (pt) 2021-05-25
PL2056832T3 (pl) 2017-09-29
JP2014040448A (ja) 2014-03-06
UA99105C2 (ru) 2012-07-25
PH12013501627A1 (en) 2014-11-10
UY30551A1 (es) 2008-03-31
AU2011205164A1 (en) 2011-08-25
ZA200900991B (en) 2010-02-24
BRPI0715712B1 (pt) 2021-03-23
SI2056832T1 (sl) 2017-07-31
JP5385139B2 (ja) 2014-01-08
RU2476223C2 (ru) 2013-02-27
CO6150163A2 (es) 2010-04-20
TW200817412A (en) 2008-04-16
RS55884B1 (sr) 2017-08-31
AR062451A1 (es) 2008-11-12
RU2009104330A (ru) 2010-09-27
CL2007002421A1 (es) 2008-04-04

Similar Documents

Publication Publication Date Title
HUE031939T2 (hu) Orális adagolásra alkalmas, triazol[4,5-d]pirimidin származékot tartalmazó készítmények
US20080045548A1 (en) Pharmaceutical Compositions
JP5285105B2 (ja) 医薬品組成物
AU2009254574B2 (en) Solid pharmaceutical formulations comprising BIBW 2992
EA025852B1 (ru) ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ РИЛПИВИРИН HCl И ТЕНОФОВИРА ДИЗОПРОКСИЛФУМАРАТ
HUE035241T2 (hu) Darunavir kombinációs készítmények
JP7550393B2 (ja) 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
EP3052086A1 (en) Pharmaceutical composition comprising low dose active pharmaceutical ingredient and preparation thereof
KR20170055886A (ko) 티카그렐러를 포함하는 약제학적 조성물
Alotaibi Development and Optimization of Liquisolid Tablets Containing Tadalafil and Dapoxetine as a Combined Therapy for Male Sexual Dysfunction
TR2023006078T2 (tr) Favi̇pi̇ravi̇ri̇n hemen salimli kompozi̇syonu
HUE027829T2 (hu) Nem kristályos lopinavirt és kristályos ritonavirt tartalmazó dózisforma